Skip to Main Content

While pharmaceutical regulatory authorities in other countries are employing creative ways like video-based remote inspections to fulfill their obligations to the public, the U.S. Food and Drug Administration remains committed to conventional on-site inspections. By September 2020, the Covid-19 pandemic had precipitated a virtual pause in drug inspections: Roughly 85% of inspections had been curbed within U.S. borders and 99.5% outside the country.

Inspecting manufacturing facilities is a vital part of drug approval and production, and backlogs can cause huge delays, creating drug shortages in the global supply chain and threatening another global health crisis. Inspections are a key tool the FDA uses to ensure that drug producers adhere to manufacturing and record-keeping requirements, which ensures the safety of drugs on the market. Drug producers cannot legally operate without passing initial or recurring inspections.


Sticking with the traditional approach to inspections as a pandemic made them nearly impossible embodies a broader phenomenon across government: For years, U.S. agencies have been slow to adopt new remote and automated inspection technologies, many of which promise greater public health and safety at lower costs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!